ENST00000588952.5:c.-284+11452C>G
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The ENST00000588952.5(DNMT1):c.-284+11452C>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.134 in 152,130 control chromosomes in the GnomAD database, including 1,528 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.13 ( 1528 hom., cov: 32)
Consequence
DNMT1
ENST00000588952.5 intron
ENST00000588952.5 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 0.153
Publications
5 publications found
Genes affected
DNMT1 (HGNC:2976): (DNA methyltransferase 1) This gene encodes an enzyme that transfers methyl groups to cytosine nucleotides of genomic DNA. This protein is the major enzyme responsible for maintaining methylation patterns following DNA replication and shows a preference for hemi-methylated DNA. Methylation of DNA is an important component of mammalian epigenetic gene regulation. Aberrant methylation patterns are found in human tumors and associated with developmental abnormalities. Variation in this gene has been associated with cerebellar ataxia, deafness, and narcolepsy, and neuropathy, hereditary sensory, type IE. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2016]
DNMT1 Gene-Disease associations (from GenCC):
- autosomal dominant cerebellar ataxia, deafness and narcolepsyInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Genomics England PanelApp, PanelApp Australia, Orphanet, Labcorp Genetics (formerly Invitae)
- hereditary sensory neuropathy-deafness-dementia syndromeInheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.193 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|
Ensembl
Frequencies
GnomAD3 genomes AF: 0.134 AC: 20336AN: 152012Hom.: 1532 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
20336
AN:
152012
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.134 AC: 20321AN: 152130Hom.: 1528 Cov.: 32 AF XY: 0.131 AC XY: 9775AN XY: 74372 show subpopulations
GnomAD4 genome
AF:
AC:
20321
AN:
152130
Hom.:
Cov.:
32
AF XY:
AC XY:
9775
AN XY:
74372
show subpopulations
African (AFR)
AF:
AC:
3488
AN:
41516
American (AMR)
AF:
AC:
1997
AN:
15260
Ashkenazi Jewish (ASJ)
AF:
AC:
469
AN:
3470
East Asian (EAS)
AF:
AC:
1048
AN:
5158
South Asian (SAS)
AF:
AC:
882
AN:
4824
European-Finnish (FIN)
AF:
AC:
989
AN:
10600
Middle Eastern (MID)
AF:
AC:
71
AN:
294
European-Non Finnish (NFE)
AF:
AC:
10934
AN:
67982
Other (OTH)
AF:
AC:
362
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
872
1744
2617
3489
4361
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
668
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.